The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact Information: Amphastar Pharmaceuticals, Inc. Bill Peters Chief Financial Officer (909) 980-9484 SOURCE: Amphastar Pharmaceuticals, Inc. View source version on accesswire.com: https://www.accesswire.com/742570/Amphastar-Pharmaceuticals-Receives-FDA-Approval-for-Naloxone-Hydrochloride-Nasal-Spray-4mg